Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for building renal anemia animal model

A technology of animal model and construction method, which is applied in the field of medical engineering, and can solve problems such as models not being commonly used, lack of animal models of renal anemia, and difficult standardization of surgery

Inactive Publication Date: 2019-02-05
魏日胞
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

5 / 6 animal model of nephrectomy is not commonly used because the operation is not easy to standardize, the clinical and pathological manifestations fluctuate greatly, and the degree of anemia is not severe.
Although aristolochic acid was used to induce the CKD model in the past, there is still a lack of research on the animal model of renal anemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for building renal anemia animal model
  • Method for building renal anemia animal model
  • Method for building renal anemia animal model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] The preparation of embodiment 1 renal anemia mouse model

[0034] In the first step, aristolochic acid was prepared into a 0.4 mg / mL solution with PBS.

[0035] In the second step, the C57BL / 6 mice were allowed to eat and drink freely for a week for adaptive feeding, and then the mice were divided into groups of 10, divided into 3 groups, and a group of mice without injection was used as the control group (referred to as the control group). con group), a group of mice were injected with aristolochic acid solution every 2 days (called AA / 2d group), and a group of mice were injected with aristolochic acid solution every 3 days (called AA / 3d group).

[0036] The mice in the AA / 2d group were injected intraperitoneally with aristolochic acid solution, and the injection volume and frequency were: 3 mg / kg, once every 2 days, for 6 consecutive weeks.

[0037] The mice in the AA / 3d group were intraperitoneally injected with aristolochic acid solution, the injection volume and fre...

Embodiment 2

[0038] Embodiment 2 detects each index of mouse

[0039] After 6 weeks of injection, the administration was stopped, and the renal function (serum creatinine, blood urea nitrogen), anemia (hemoglobin, hematocrit), and erythropoietin (EPO) levels of the three groups were detected, and the pathological changes of the kidneys were observed to determine the occurrence of Renal impairment and anemia.

[0040] 1. Renal function (serum creatinine, blood urea nitrogen) detection

[0041] The mice were injected intraperitoneally with aristolochic acid for 6 weeks, and continued to observe until 9 weeks and 12 weeks after drug withdrawal, and the above three time point indicators of serum creatinine (Scr) and blood urea nitrogen (BUN) were detected by enzymatic method. Serum creatinine indicators such as Figure 1A As shown, the serum creatinine level of the aristolochic acid AA / 2d group and AA / 3d group increased significantly at 6 weeks, compared with the control group, the difference...

Embodiment 3

[0129] Embodiment 3 model correction test

[0130] In order to confirm that the model of aristolochic acid-induced renal injury is a renal anemia model, the inventors gave EPO (3.5IU / g subcutaneous 1 / week) to the model group (AA / 3d group) after stopping the administration of aristolochic acid. At 6 weeks, the hemoglobin levels of the three groups (control group, model group, and model group treated with EPO) were measured. It was found that erythropoietin can significantly correct the renal anemia induced by aristolochic acid, and the hemoglobin in the model group rose from 94g / L to 141g / L, and basically returned to normal. This anemia model was verified again as a renal anemia model, and the results are shown in Table 1 Show.

[0131] Table 1 Comparison of hemoglobin in each group after EPO

[0132]

[0133] Note: Compared with control mice, *** P▲▲▲ P<0.001

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for building a mouse renal anemia animal model. The method comprises the following steps: 1) preparing a 0.4 mg / mL aristolochic acid solution from aristolochic acid with PBS (Phosphate Buffer Saline); 2) injecting the aristolochic acid solution into the enterocoelia of a mouse for 6 weeks, 3 mg / kg once every 3 days, and detecting anemia, renal function index, renalpathology and capability of secretion of hemopoietin; 3) stopping administration for 6 weeks, and observing the previous indexes again. The mouse renal anemia animal model built by the method is stable and has high modeling rate, and the problem that renal anemia has a higher incidence rate among chronic kidney diseases but a mature renal anemia animal model is lacked at present is solved.

Description

technical field [0001] The invention belongs to the technical field of medical engineering, and relates to a method for constructing an animal model, in particular to a method for constructing a renal anemia animal model using mice as model animals. Background technique [0002] In recent years, chronic kidney disease (CKD) has become a global public health problem. According to statistics, the prevalence of chronic kidney disease in the adult population in my country is 10.8% (about 120 million), and there are more than 2 million patients in need of dialysis nationwide. Uremic patients. Renal anemia is one of its most common complications, with a prevalence rate of 40% to 60% (CatropH.Kidney Int.2010; 77:269–71; Maxwell PH.Kidney Int.1993; 44:1149–62 ), insufficient production or secretion of erythropoietin is recognized as the main cause of renal anemia. Renal anemia can accelerate the progression of renal function, induce cardiovascular events, reduce the quality of life...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/36A61K49/00
CPCA61K31/36A61K9/0019A61K49/0008
Inventor 魏日胞汪杨
Owner 魏日胞
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com